Abstract

To analyze the clinical efficacy and safety of monotherapy and dual therapy in patients with early ischemic stroke. The study was conducted from August 2020 to August 2021, and 80 patients with early ischemic stroke who received treatment at our hospital during this period were selected as the study population. They were randomly divided into a control group and an observation group, with 40 patients in each group. The control group received conventional monotherapy, while the observation group received conventional dual therapy. The efficacy and safety indicators of the two groups were compared. The treatment efficacy, functional recovery, blood indicators and inflammation markers in the observation group were all superior to those in the control group (all, p<0.05); there was no significant difference in the drug safety profile between the two groups (p>0.05). The dual antiplatelet therapy is more ideal than monotherapy for treating patients with early ischemic stroke. It can further promote the recovery of neurological and cognitive function, improve hematological and inflammatory response indicators in patients and the safety of this r egimen is comparable to monotherapy.